A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. [electronic resource]
Producer: 20120611Description: 779-86 p. digitalISSN:- 1573-0646
- Administration, Oral
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzodioxoles -- administration & dosage
- Canada
- Deoxycytidine -- administration & dosage
- Disease Progression
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Pancreatic Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Quinazolines -- administration & dosage
- Treatment Outcome
- Tumor Burden -- drug effects
- src-Family Kinases -- antagonists & inhibitors
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.